FA Study Finds Frataxin Levels in Cells Unaffected by Interventions

Pfizer has published a study with potentially important implications for future therapeutic targets to treat Friedreich’s ataxia (FA). The study, titled “Perturbation of cellular proteostasis networks identifies pathways that modulate precursor and intermediate but not mature levels of frataxin,” was conducted through Pfizer’s Rare Disease Research…